Chr Hansen Holding A/S, a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries, is pleased to announce the EU approval of their HMO 6’-Sialyllactose sodium salt (6’-SL) as the final addition to their MyOli™ 5 HMO Mix. This approval grants exclusive proprietary protection for the next five years and authorizes the highest use level of 6’-SL in infant formula and follow-on formula (0.70 g/L) in the EU.
The newly authorized 6’-SL HMO, marketed as MyOli™ 6’-SL HMO, offers several benefits, including reducing the risk of harmful bacteria adhesion and their proteins, as well as supporting brain development in infants through the supply of sialic acid, a crucial building block for neurons.
With this EU authorization, Chr. Hansen has now obtained approval for all five HMOs in its MyOli™ 5 HMO Mix. The mix comprises 2’-FL, 3-FL, LNT, 3’-SL, and 6’-SL, all of which are approved at the industry’s highest use levels for infant formula and follow-on formula.
“The fact that Chr. Hansen MyOli™ 5 HMO Mix is now approved for use in the EU at the highest use levels is an important milestone. It means that Chr. Hansen can now supply a blend of five HMOs bringing infant nutrition solutions closer to breast milk, to the benefit of infants who cannot be breastfed for various reasons. The European approval is also an important step towards using HMOs at natural concentration levels in infant formula and follow-on formula,” says Jesper Sig Mathiasen, senior vice president, Chr. Hansen HMO.
HMOs (Human Milk Oligosaccharides) are the third most abundant solid component found in breast milk and are known to exist in various structural variations. The diverse range of HMOs contributes to their numerous benefits.
Chr. Hansen remains committed to pioneering innovative solutions in the bioscience industry, providing safer and more effective products for infant nutrition.
